Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen ...

A new research paper was published in Oncotarget's Volume 14 on October 4, 2023, entitled, "Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells." ...

Serial circulating tumor DNA analysis can demonstrate rapid clonal dynamics that evolve during response and resistance to both standard chemotherapy and targeted therapy of BRAF-mutant colon cancer ...

LUT014 gel significantly reduces acne-like rashes from anti-EGFR therapies in colorectal cancer patients, improving quality of life. The phase 2 trial showed 70% improvement with high-dose gel, ...

CHICAGO – Patients with colorectal cancer who had acneiform rash and applied LUT014 gel, an investigational topical BRAF inhibitor, were more likely to experience improvement of their rash compared ...

BERLIN — Re-treatment with an anti-epidermal growth factor receptor (EGFR) agent is effective in patients with chemorefractory metastatic colorectal cancer (mCRC) with RAS and BRAF wild-type tumors ...

A research team from the UCLA Health Jonsson Comprehensive Cancer Center, the University of Texas MD Anderson Cancer Center, and collaborators have demonstrated that a novel topical BRAF inhibitor gel ...

A mini oral session at ESMO of targeted therapy in non-small cell lung cancer included treatments that showed effectiveness in brain metastases. Targeted therapy continues to make waves in metastatic ...

A total of 166 patients with mCRC BRAF-V600E were included in the study from discovery (n = 46), validation (n = 52) and control (n = 68) cohorts. WES of germline DNA, baseline tumor DNA and/or ...

“These results point to a highly active compound that has the potential to fill a substantial unmet need for an oral, well-tolerated precision therapy option in the current NSCLC therapeutic landscape ...